FDA Releases Rules for Biosimilar Product Promotion Guidance
Published Date: 12/10/2025
Notice
Summary
The FDA just released clear rules for companies on how to advertise and label prescription biological drugs, including biosimilars and interchangeable biosimilars. This helps drug makers know what’s allowed when promoting these products, making sure info is honest and easy to understand. The new guidance is official as of December 10, 2025, so affected companies should update their ads soon to avoid any hiccups.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 1 costs, 1 mixed.
New FDA Ad Rules for Biologics
On December 10, 2025, FDA issued final guidance on promotional labeling and advertising for prescription reference biological products, biosimilar products, and interchangeable biosimilar products. The guidance tells firms how to identify products, present study information, present data not in FDA-approved labeling (when consistent with labeling), compare biosimilars and reference products, and submit promotional communications to FDA; the recommendations apply regardless of medium (paper or digital).
Pharmacy Substitution Clarified
The guidance reiterates that an interchangeable biosimilar product may be substituted for the reference product without the prescribing healthcare provider's intervention (section 351(i)(3) of the Public Health Service Act). Decisions about pharmacy-level substitution remain subject to State pharmacy law.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2025-22426 — Agency Information Collection Activities: Proposed Collection; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to collect some info from the public. They’re asking for comments by February 9, 2026, to make sure the process is clear, useful, and not too much work. This helps CMS do its job better without wasting anyone’s time or money.
Next: 2025-22428 — Determination Pursuant to Section 102 of the Illegal Immigration Reform and Immigrant Responsibility Act of 1996, as Amended
Starting December 10, 2025, the Department of Homeland Security is speeding up the building of barriers and roads along the Texas border by temporarily skipping some usual rules and laws. This move helps stop illegal crossings and keeps the country safer, focusing on quick action without delays. It affects border communities and aims to boost security without mentioning extra costs or funding changes.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in